Lakewood-Amedex Biotherapeutics has become one of the most expensive stocks to short on the Nasdaq this week, with its borrow market tightening at a pace that is almost without precedent for a name this small.
The cost-to-borrow story is the standout. At 423% annualised as of April 30 — nearly tripling from 161% just three sessions earlier on April 27 — borrowing LABT now carries costs that rival the most heated meme-stock episodes. That kind of acceleration is rare. It typically signals a sudden, sharp spike in demand for borrows that the lending pool simply cannot absorb at scale.
The availability data confirms the squeeze is real. As recently as April 27, availability of shares to borrow stood at roughly 1,135% of outstanding short interest — a loose, unconstrained lending market. By April 30, it had collapsed to just 26%. That means roughly three shares are already borrowed for every one still sitting available in the pool. The move from loose to very tight happened in four sessions. The lending pool for this name is, for practical purposes, nearly exhausted.
Availability tightening of that speed tends to reflect either a wave of fresh short sellers entering simultaneously, or prime brokers recalling lent shares — or both. The utilisation picture reinforces this: on April 27, roughly 11% of available inventory was on loan. By April 30 that had reached 100%, the upper bound, and the highest level in the past year. Every share in the pool is now out.
The price action adds another layer. The stock rebounded 29% on May 1 after falling more than 53% over the preceding week. A week-on-week loss of that magnitude in a name where the lending market is now fully drawn down suggests forced moves in both directions — heavy selling that triggered the price collapse, followed by a sharp recovery that may in part reflect covering activity. No earnings event is scheduled, and the only historical corporate event on record is a January 2026 announcement, with no associated price-reaction data available.
What to watch next: whether borrow availability recovers — any move back above 100% would signal the acute demand pressure has eased — or whether cost-to-borrow holds above 400%, which would mark a full consolidation of the new, structurally tighter lending regime for this name.
See the live data behind this article on ORTEX.
Open LABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
